Trial Profile
Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Elraglusib (Primary) ; Carboplatin; Doxorubicin; Gemcitabine; Irinotecan; Lomustine; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Astrocytoma; CNS cancer; Colorectal cancer; Glioblastoma; Glioma; Haematological malignancies; Liver cancer; Male breast cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Pancreatic cancer; Parotid cancer; Peritoneal cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Actuate Therapeutics
- 29 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results evaluating the efficacy and safety of elraglusib in combination with GnP in advanced pancreatic cancer patients were presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results assessing Plasma cytokine profiles and survival outcomes , presented at the 59th Annual Meeting of the American Society of Clinical Oncology